Vivo Bio Tech Ltd
VIVO.IN
$0.54
Closing
▼-0.88%
1D
▲36.47%
YTD
Market cap
$8.08M
52 week high
$0.67
52 week low
$0.25
Volume
28,565
Check if the stock is halal
Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.
We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.
Get started from just $3.99/month
Market cap
$8.08M
Analysts' Rating
-
Price Target (Mean)
Unable to collect data for some field(s).
Total Analysts
0
P/E
17.69
Operating Margin
27.58%
Beta
1.59
Revenue Growth (Annual)
-5.68%
52 week high
$0.67
52 week low
$0.25
Div. Yield
%
EPS Annual Growth
0.00
Note on Purification and Zakat
- Purification and Zakat (for long-term investing) calculations are in USD per share and based on AAOIFI methodology. AAOIFI requires purification every financial period (e.g. quarterly).
- If you follow S&P Shariah’s Dividend-only purification, then remove the impure income % from the dividends you receive. No purification required for non-dividend paying stocks, according to S&P Shariah.
- For Zakat, if you did not invest in a company from a long term perspective, then consider the shares as trading goods and give 2.5% of the total value if a year has passed on them.
Company Profile
Vivo Bio Tech Limited is an India-based full service pre-clinical clinical research organization (CRO). The Company offers drug development and discovery services to pharmaceutical and biotech companies across the world. The Company offers services in the areas of In vivo and In vitro toxicity studies, pharmacological investigations, pharmacokinetic and toxicokinetic studies, genotoxicity screening, analytical services, and other. It provides both regulatory and non-regulatory IND enabling preclinical development services. It is engaged in screening and evaluating molecules for various pharmacological and therapeutic properties. Specifically for oncology, the Company provides designing and development of syngeneic/xenograft models for evaluation of anti-cancer agents. The Company also customizes In vivo drug metabolism and pharmacokinetics (DMPK) studies to help profile drug candidate in both rodent and non-rodent animal models.
